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Abstract 
OBJECTIVE: Rapid and early detection of patients at risk to develop sepsis remains 
demanding. Heparin-binding protein (HBP) has previously demonstrated good prognostic 
properties in detecting organ dysfunction among patients with suspected infections. This 
study aimed to evaluate the plasma-levels of HBP as a prognostic biomarker for infection-
induced organ dysfunction among patients seeking medical attention at the emergency 
department. 
DESIGN: Prospective, international multicenter, convenience sample study 
SETTING: Four general emergency departments at academic centers in Sweden, Switzerland 
and Canada. 
PATIENTS: All emergency encounters among adults where one of the following criteria 
were fulfilled: a) respiratory rate >25 breaths per minute; b) heart rate >120 beats per minute; 
c) altered mental status; d) systolic blood pressure <100 mm Hg; e) oxygen saturation <90% 
without oxygen; f) oxygen saturation <93% with oxygen; g) reported oxygen saturation 
<90%. 
INTERVENTION: None 
MEASUREMENTS AND MAIN RESULTS: A total of 524 ED patients were prospectively 
enrolled, of these 236 (45%) were eventually adjudicated to have a non-infectious disease.  
Three hundred forty-seven patients (66%) had or developed organ dysfunction within 72 
hours, 54 patients (10%) were admitted to an intensive care unit (ICU), and 23 patients (4%) 
died within 72 hours.  For the primary outcome, detection of infected-related organ 
dysfunction within 72 hours, the AUC for HBP was 0.73 (95% C.I. 0.68-0.78) among all 
patients and 0.82 (95% C.I. 0.76-0.87) among patients confidently adjudicated to either 
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infection or no infection. Against the secondary outcome, infection leading to admittance to 
the ICU, death or a persistent high SOFA-score due to an infection (SOFA-score ≥5 at 12-24 
hours) HBP had an AUC of 0.87 (95% C.I. 0.79-0.95) among all patients and 0.88 (95% C.I. 
0.77-0.99) among patients confidently adjudicated to either infection or non-infection.  
CONCLUSIONS: Among patients at the emergency department, HBP demonstrated good 
prognostic and discriminatory properties in detecting the most severely ill patients with 
infection. 
Keywords: HBP, intensive care, emergency department, sensitivity, specificity, multicenter 
study 
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Introduction 
 
Sepsis is a complex and life-threatening condition caused by a dysregulated immune response 
to infection, which leads to damages at both cell and tissue levels. Sepsis is common and 
affects approximately 700 / 100 000 every year (1-3), thus being more prevalent than the 
most common forms of cancer (i.e. prostate, breast, skin, bowel, lung, malignant melanoma 
and urinary tract cancer) (4). The mortality in sepsis is high, with more than 5 million deaths 
worldwide annually (5). Early recognition and treatment of sepsis is of outmost importance 
for the outcome (6). 
Predicting which patients presenting with an infection that will progress to develop infection-
induced organ failure in the emergency department (ED) is challenging. The symptoms of 
sepsis can be vague and are often misinterpreted. In a study by Gille-Johnson et al, 23% of 
the patients with symptoms for an infection and intact organ function when presenting at the 
ED developed severe sepsis within 24 hours (7). This further implicates the need for reliable 
sepsis biomarkers. 
The quest for new useful biomarkers in sepsis has been challenging (8). In the era of multi-
omics, biomarkers may be the path towards a more personalized approach to the septic 
patient (9). Heparin-binding protein (HBP) is a promising candidate (10). It is a constitutively 
expressed protein stored in the azurophilic granulae and secretory vesicles of neutrophils 
(11); as such its release results in it being among the first detectable markers of infection. 
HBP serves many important biological functions but its vascular actions are most relevant to 
the development of organ failures. HBP has been shown to be the link in neutrophil-derived 
induction of vascular leakage (12). It has subsequently been shown to reliably predict the 
development of severe sepsis among febrile patients (10,13). HBP has also been evaluated as 
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a prognostic or predictive marker in bacterial meningitis, urinary tract infections, infections in 
lung transplantation and cystic fibrosis patients (14-17).  
Prior studies of HBP have focused primarily on patients with suspected infection. To truly 
validate HBP, as a marker for infection-related organ dysfunction (OD) in a clinical setting, 
the present study included the full spectrum of patients presenting at the ED, both with and 
without infections. Thus, the objectives of the current study were to 1) evaluate HBP as a 
prognostic biomarker for infection-induced organ dysfunction among patients seeking 
medical attention at the emergency department regardless if there were a suspicion of 
infection or not; and 2) to compare the prognostic properties of HBP to other biomarkers 
currently in use.  
Material and Methods 
This was a prospective, multicenter, observational, convenience sample study of ED patients 
(ClinicalTrials.gov NCT02366650) conducted at two Swedish (Skåne University Hospital, 
Lund and Helsingborg Hospital, Helsingborg), one Swiss (Inselspital University Hospital, 
Bern) and one Canadian (St Paul’s Hospital, Vancouver) academic centers. The size of the 
catchment areas of the respective hospital varied from 200,000 to 1,500,000 inhabitants and 
the annual visits of the EDs range from 45,000 to 115,000 per year. Patients were recruited 
during February 2015 and then again from January to March 2016 in Lund (Sweden), 
February to April 2015 in Bern (Switzerland), March to April 2015 in Vancouver (Canada) 
and April to December 2015 in Helsingborg (Sweden). The Institutional Review Board for 
Human Research approved the trial at each center (Lund and Helsingborg 2014/41, Bern 
KEK 315/14, Vancouver H11-00505).  
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Patient population  
Patients were enrolled upon presentation to the ED when fulfilling the following inclusion 
criteria: 1) age over 18 years 2) at least one of the following criteria irrespectively of cause to 
the condition a) respiratory rate >25 breaths per minute; b) heart rate >120 beats per minute; 
c) altered mental status; d) systolic blood pressure <100 mm Hg; e) oxygen saturation <90% 
without oxygen; f) oxygen saturation <93% with oxygen; g) reported oxygen saturation 
<90%. The inclusion criteria were adopted from the  RETTS™-triage system, which is 
system used at the majority of Emergency Departments in Sweden (18). The vital parameters 
correspond to Red RETTS (demanding immediate attention) or Orange RETTS (demanding 
attention within 1 hour).   
Patients fulfilling the inclusion criteria were asked to participate in the study and to give their 
written informed consent. If the patient was unable to give an informed consent their next-of-
kin was asked for permission. If the patient died without being able to give a consent (and no 
consent from next-of-kin was available), the use of data and samples was requested at the 
local ethical committee. The inclusion or exclusion of the data and samples was in 
accordance with ethical board decision. If patients or their next-of-kin denied or withdrew 
consent, they were excluded from the study. 
Data collection 
Patient data collected at enrollment included demographics, vital signs (heart rate, respiratory 
rate, blood pressure, arterial oxygen saturation [SaO2], and mental status). Vital signs were 
documented at enrollment and during the further course, according to the observational study 
design. The cause for the visit to the ED was noted by the including physician. Laboratory 
testing (white blood cell count [WBC], platelets, C-reactive protein [CRP], prothrombin time 
test presented as international normalized ratio [INR], activated partial thromboplastin time 
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[aPTT], bilirubin, serum creatinine, and plasma lactate) was performed. Microbiological 
investigations were performed at the discretion of the treating physicians, and results were 
obtained for this study. The time to and treatment duration of antibiotics was registered.  Data 
on comorbid conditions, concomitant medication, new medications (including intravenous 
fluids and vasopressors), and if the patient was transferred to an intensive care unit (ICU) 
were recorded. OD and mortality within the 72-hour study period was monitored.  
Sample Collection and Biomarker Assays  
Venous blood samples for the determination of biomarkers were drawn in EDTA tubes from 
patients at enrollment. Samples were centrifuged, stored at –80°C within 2 hours of 
collection. HBP and procalcitonin (PCT) were subsequently analyzed in a centralized 
laboratory. HBP was analyzed in duplicate using the Axis-Shield HBP microtiter plate 
enzyme-linked immunosorbent assay (Axis-Shield Diagnostics, Dundee, United Kingdom) 
and PCT by the ADVIA Centaur BRAHMS PCT assay (Siemens Healthcare Diagnostics, 
Surrey, United Kingdom). WBC, CRP, and lactate analyses were performed at the Clinical 
Chemistry Departments at each site. Prior to analysis each sample was visually screened for 
hemolysis.  
Definition of Outcomes  
The primary outcome was the presence or development of infection-induced OD within the 
72-hour time period from enrollment. OD within 72 hours from enrollment was defined 
according to the Sepsis-2 definition since this definition was the definition in use when the 
study was conducted.  
The criteria for OD for sepsis-2 were adapted from consensus criteria for sepsis syndrome 
(18) (19). OD was defined as present when any definition of organ dysfunction was met 
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within 72 hours from admission in the absence of preexisting pathology that could explain the 
abnormal results (for definition of organ dysfunction see supplemented table S1, 
http://links.lww.com/SHK/A852). Plasma lactate elevation was not included as a criterion for 
OD as its utility was evaluated as a marker in the study. If the systolic blood pressure was 
<90 mmHg or the drop in blood pressure was >40 mmHg but the patient was sent home 
within 12 hours from the ED and had not received any fluid, this was not regarded as a 
circulatory OD (6 patients were redefined by this additional criterion). If patients were 
discharged from the hospital before the 72-hour period and there was no evidence of OD 
during the hospitalization, they were assumed to have no subsequent OD.  
For the calculation of SOFA-score a modified SOFA-scale was used. The reason was that the 
majority of patients were treated on regular hospital wards and thus PaO2/FiO2 was not 
available (table S2, http://links.lww.com/SHK/A852). The FiO2 was estimated using a 
conversion table (supplemented table S3, http://links.lww.com/SHK/A852).  
A critical disease was defined as condition leading to death or admittance to the ICU within 
24 hours or a SOFA-score ≥5 at 12-24 hours post enrollment. The time when the organ 
dysfunction developed was evaluated and categorized in 4 groups; (i) present at inclusion, (ii) 
developing within 0-12 hours, (iii) 12-24 hours,  (iv) 24-48 hours, or  (v) 48-72 hours after 
admittance to the ED. A critical infection was defined as a critical disease caused by an 
infection. 
The presence of an infection was assessed by two independent Infectious Diseases (ID) 
consultants (F.K. and A.L. or P.Å.) blinded to the results of HBP and PCT.  If the 
classification differed a third ID physician reviewed the data and the patient was discussed by 
all three physicians to reach consensus. The patients were divided into five groups; (i) 
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bacterial infection, (ii) probable bacterial infection, (iii) probably not an infection, (iv) no 
infection and, (v) viral infection 
(I) Bacterial infection (hereafter called Infection) was defined as a microbiological or 
a radiological finding together with symptoms of infections from that site, or a 
positive blood culture with a relevant pathogen. Patients with chronic obstructive 
pulmonary disease (COPD) and lung symptoms with concomitant radiological 
findings were defined as probable infections (II).  
(II) Probable bacterial infection (hereafter called probable infection) was defined as 
the presence of an infection causing the current disease as evaluated by the 
reviewing physician but lack of criteria for a bacterial infection (i.e. presence of a 
microbiological, or a radiological finding from the suspected site of infection OR 
a positive blood culture).  
(III) Probably not an infection was defined as most likely a condition not caused by a 
bacterial infection by the reviewing physician but not fulfilling the criteria no 
infection (e.g. the patient may have had a positive culture from an irrelevant site, 
or a dose of antibiotics might have been given). 
(IV) No infection was defined as the presence of a clear non-bacterial infection 
diagnosis, no positive cultures, no use of antibiotics, and survival of at least 12 
hours post-inclusion.  
(V) Viral infection was defined as: 
a. A finding of a viral agent by PCR likely of giving rise to the present disease 
and the absence of any probable bacterial cause was defined as a viral cause 
OR 
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b. Patients diagnosed with a viral infection by the treating physician, with 
laboratory and microbiological findings in agreement, and no use of 
antibiotics but with no certain findings of a viral agent 
Statistical Methods 
Means, medians, standard deviations (SDs), and interquartile ranges (IQRs) were reported as 
appropriate. Differences in frequencies between groups were tested with the chi2-test and 
Fisher’s exact test as appropriate and differences between group medians with the Mann-
Whitney U test. The Jonckheere-Tepstra test was used to asses ordered differences between 
classes. Area under the receiver operating curve (AUCs) were calculated to assess the 
diagnostic power of each marker. Youden’s index was used to calculate the optimal cut-off 
for HBP. For analysis of risk versus HBP-levels, the relationship was fitted using Local 
Weighted Scatterplot Smoothing (LOWESS). To assess the performance of HBP in relation 
to proportion of infected patients only patients able to be confidently adjudicated as to the 
presence or absence of infection were included (n=332, group I and IV). Samples from the 
groups I and IV were drawn (with replacement) to mimic cohorts with the proportion of 
infected patients ranging from 10% to 100% in steps of 1%. For each proportion of infected 
patients 100 stochastic cohorts (each with 1000 patients) were drawn and the AUC-values for 
the different biomarkers were calculated and the median was calculated and plotted. To 
assess the association between biomarkers and infection or organ dysfunction/critical disease, 
respectively,  a logistic regression was then fitted.  First, each biomarker was dichotomized 
according to their respective cut-off value suggested by Youden’s index. Next, a logistic 
regression was fitted using infection and organ dysfunction/critical disease as well as the 
interaction between them as covariates. In no cases the interaction term was significant and 
therefore a new logistic regression was fitted without the interaction term and the 
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corresponding odds ratios (ORs) were calculated. R (R Core Team (2017) R: A language and 
environment for statistical computing. R Foundation for Statistical Computing, Vienna, 
Austria. URL https://www.R-project.org/) was used for statistical computation with the 
following packages: readxl, ggplot2, grid, gridExtra, clinfun, pROC, epiR, dplyr and Hmisc.  
P-values lower than 0.05 were regarded as significant.  
RESULTS 
Patient Characteristics  
A total of 718 ED patients were prospectively enrolled. Patients with WBC >50 x 109/L or <3 
x 109/L or missing WBC values were excluded from the study since HBP is a neutrophilic 
protein and excess or lack of neutrophils may give rise to erroneous results. Furthermore, 
samples with any sign of hemolysis were excluded, since hemolysis could indicate lysis of 
white blood cells and hence concomitant release of HBP to the blood. In total, 194 patients 
(27%) were excluded, of these 146 patients (75%) were excluded due to hemolysis (Figure 
1). Details on patient characteristics are presented in Table 1 and characteristics subdivided 
per site can be found in Table S4 (http://links.lww.com/SHK/A852) and Figure S1 
(http://links.lww.com/SHK/A849).   
HBP as predictor of infection-related organ dysfunction 
HBP-levels were analyzed according to both the likelihood of infection (group I-V) and 
presence of organ dysfunction (OD) during the 72 hours study period (Figure 2). Overall, 
infected patients had significantly higher HBP-levels than non-infected patients. HBP levels 
were highest (median 18.3 ng/mL, IQR 9.3-32.7 mg/mL in infected patients with OD, these 
being significantly higher values than in infected patients without OD (median 9.4 mg/mL, 
IQR 7.4-17.6 ng/mL) (p=0.036). 
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Three hundred thirty-two patients were able to be confidently adjudicated to have presented 
with infection or non-infectious cause of illness (group I and IV). To investigate how specific 
HBP was in detecting infection-induced OD, ROC curves were constructed and the AUCs 
were calculated for HBP, PCT, CRP, WBC, and lactate among these patients. CRP had the 
highest AUC followed by HBP (Table 2). Suggested cut-off values were calculated using 
Youden’s index and discriminatory values were calculated (Table 2).  
To assess how HBP might perform prospectively (without the benefit of post-hoc 
adjudication as to the presence of infection), sensitivity analyses were performed in the entire 
cohort (n=524, group I-V). We performed a similar analysis including patients with 
hemolytic samples (n=670, n=426), as well as subdivision per site) (supplemented table S5 
and S6, http://links.lww.com/SHK/A852). Although the AUC was slightly lower in these 
analyses HBP performed well as a predictor of OD in all analyses  (supplemented table S5 
and S6, http://links.lww.com/SHK/A852). 
HBP levels are related to the severity of the disease 
To assess the potential bias that patients with infections were more severely ill at presentation 
than non-infected patients, they were stratified based on number of dysfunctional organs 
(Figure 3). For every number of dysfunctional organs patients with infection (n=96, group I) 
had significantly higher HBP-levels than non-infected patients (n=236, group IV). Infected 
patients with more than 4 dysfunctional organs had the highest HBP levels (median 31.9 
ng/mL, IQR 22.9-110.7 ng/mL), with a significant increase in HBP-levels according to 
number of dysfunctional organs (p=0.00084)  In non-infected patients HBP levels were lower 
overall, though a similar significant increase existed wherein HBP levels were highest in 
those with more than 4 dysfunctional organs (p=0.019). The same pattern was true when 
assessing SOFA-scores at admission instead of number of dysfunctional organs (Figure S2, 
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http://links.lww.com/SHK/A850). Altogether, these analyses suggest that the level of HBP at 
presentation is increased predominantly as a response to infection as well as to the severity of 
disease.  
HBP is a good predictor of infection-related admission to intensive care or mortality 
An important property of a sepsis biomarker is to correctly identify patients with substantial 
increased risk of rapid clinical deterioration. Thus, to study the prognostic capacity, as 
opposed to the diagnostic capacity outlined above, a composite outcome was constructed and 
analyzed as a secondary outcome. This outcome was defined as death within 24 hours or 
admission to the ICU within 24 hours. However, the decision of admitting a patient to 
intensive care in part depends on local tradition and the availability of intensive care. 
Therefore, SOFA-score was added to account for this bias. A SOFA-score ≥5 was previously 
shown to be correlated with a mortality of more than 25% (19). Hence, a SOFA-score ≥5 at 
12-24 hours was included in the composite outcome, hereafter called critical disease. An 
infection giving rise to a critical disease was defined as a critical infection (Figure 4).  
Analysis of the prognostic potential for detecting critical infection in infected and non-
infected patients (group I and IV, n=332) showed that HBP had the highest AUC 0.88 (0.77-
0.99, n=332), followed by CRP (0.86 [0.73-0.99], n=301).  Suggested cut-off values were 
calculated using Youden’s index and discriminatory values for critical infection were 
calculated (table 3).  
To verify the results, sensitivity analyses were performed with the whole cohort (n=524, 
group I-V), and the total cohort including patients with hemolytic samples (n=670 and 
n=426) as well as subdivision per site. These analyses were in agreement with the results 
above (supplemented table S7 and S8, http://links.lww.com/SHK/A852).  
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An analysis was also made to investigate the relationship between plasma-HBP and the risk 
for critical infection. Both when including only confidently adjudicated  cases  as well as 
including the whole cohort  the risk for critical infection increased as HBP-levels increased 
(Figure S3, http://links.lww.com/SHK/A851). In the whole cohort, an HBP level of over 30 
ng/mL resulted in a likelihood ratio of 8.17 (5.36-12.45) of developing critical infection, 
whereas HBP  levels less than 15 ng/mL resulted in a negative LR of 0.23 (0.09-0.56) (Table 
S7, http://links.lww.com/SHK/A852).  
Finally, an analysis of patients able to be confidently adjudicated as to the presence of 
infection (groups I and IV) with HBP >30 ng/mL but no critical infection was performed. Of 
332 patients, 320 patients (96.4%) did not experience a critical infection, and of these 26 
(8.1%) had HBP above 30 ng/mL. Characteristics of these patients can be found in 
supplemented table S9 (http://links.lww.com/SHK/A852). 
The performance of HBP is related to the proportion of infected patients in the 
population at study inclusion 
Organ dysfunction, death or admission to the ICU can be caused both by infectious and non-
infectious diseases but only infection-related events were regarded as a positive outcome in 
this study. Thus, the prognostic performance will be affected by the proportions of infected 
patients in the cohort since only infection-induced events were regarded as positive in this 
study. The proportion of infected patients will vary between different settings, time of year 
but also due to different triage systems. In the whole cohort, 34% were infected (excluding 
virus). To isolate the ability to prognosticate OD or critical infection from the ability of 
detecting infection, a sensitivity analysis was done. Only patients able to be confidently 
adjudicated as to the  presence of infection were included and new samples were drawn from 
patients with infection and non-infection, respectively, until a new cohort of 1000 patients 
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was created. The sampling was adjusted so that the proportion of infected patients varied 
from 10% to 100% in steps of 1%. For each cohort, the AUC for OD and critical infection 
was calculated (Figure 5A and 5B).  
In cohorts with a low frequency of infection, CRP was the best biomarker for infection-
induced OD but as the proportion of infected patients increased, HBP and PCT exceeded 
CRP in detecting infection-induced OD. HBP was the best marker in detecting critical 
infection across all frequencies of infection.  
To further verify this result and to dissect the individual importance of infection and organ 
dysfunction a multivariable analysis was performed with each biomarker as the dependent 
variable and infection and organ dysfunction/critical disease as covariates. The biomarkers 
were dichotomized according to their respective cut-off level suggested by Youden’s index 
(Table 4). All biomarkers except lactate were significantly associated with infection. Only 
HBP was significantly associated with OD. For critical disease HBP, CRP, WBC and lactate 
had a significant association although HBP had the highest odds ratio (OR).  
Discussion 
In this ED-based prospective observational multicenter study, HBP was a good marker for 
identification of patients at risk of developing a critical infection. Previous studies on the 
diagnostic and prognostic properties of HBP have focused on cohorts mainly consisting of 
infected patients. The present study investigated the specificity of HBP among unselected 
patients with all types of diagnoses. Hence, this study favored inclusion of patients with a 
broad spectrum of diagnoses but also more severely ill patients.  
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The primary outcome of the study was detection of any OD due to infection within 72 hours 
in accordance with a previous study (13). Against this outcome HBP had an AUC of 0.82 but 
was exceeded by CRP (AUC 0.87). The good performance of CRP is explained by the 
excellent ability of CRP in differing infectious diagnoses from non-infectious diagnoses. In 
this cohort, with a high proportion of patients presenting with or developing OD within 72 
hours, correct identification of an infection will have a large impact on the AUC (Figure 5). 
When raising the percentage of patients with infection, the performance of CRP deteriorates. 
Adjusting the fraction of infected patients to 89%, equivalent to the study by Linder et al, 
CRP had an AUC of 0.62, based on the present cohort, as compared to 0.70 in the previous 
study.  In contrast, HBP had an AUC of 0.72, based  on the present cohort, compared to 0.80 
in the Linder et al cohort (13). This was also verified in a multivariable logistic regression 
where CRP had a very high OR for infection but was not significantly associated with organ 
dysfunction. HBP was the  only biomarker of those studied that was significantly associated 
with both infection and organ dysfunction.   
OD is, however, a blunt criterion for the definition of a serious infection. Patients with 
transient OD (e.g. a SaO2<90% at one occasion) do not necessarily need to be admitted to 
intermediate or intensive care. The most important feature of a prognostic biomarker is to 
identify patients in need of special treatment. HBP demonstrated good prognostic properties 
with an AUC of 0.88 in predicting critical infections and outperformed all other markers 
studied. The cut-off value to detect a critical infection was 22.85 ng/mL. This value is in 
agreement with earlier studies that suggested cut-offs of 15 ng/mL or 30 ng/mL (10,13).  
As the severity of disease increased there was a concomitant increase in HBP-levels. 
Furthermore, higher HBP-levels were associated with higher risk for a critical infection. This 
suggests that it may be useful to have two cut-off levels for HBP. Setting the cut-off to ≥30 
ng/mL the positive predictive value was 0.27 and the positive likelihood ratio was 8.17 in 
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detecting a critical infection in the whole cohort. On the other hand, HBP <15 ng/mL had a 
negative predictive value of 0.99 and a negative likelihood ratio of 0.23. These results 
indicate that patients with HBP ≥30 ng/mL are at greater risk of having or developing a 
critical infection and will thus require close monitoring and the use of empirical antibiotic 
therapy might be considered while concomitantly investigating for possible differential 
diagnoses.  For patients with HBP <15 ng/mL the risk of an unfavorable infection-related 
outcome is low. Patients with HBP between 15 and 30 ng/mL have an intermediate risk and 
they may benefit from observation for a few hours followed by a new HBP test. However, 
consecutive HBP measurements was not part of the present study, and therefore this 
assumption is speculative. 
Patients without infection also had higher HBP levels as the number of failing organs 
increased but from lower levels of HBP compared to infected patients. Indeed, a few patients 
(n=8) without infection had HBP values above 30 ng/mL. These patients had a significantly 
increased mortality rate (38% vs 4%) compared to non-infected patients with HBP below 
30ng/mL (n=227). It is not surprising that some patients with severe non-infectious diseases 
indeed have high HBP levels. It has previously been shown that patients with neutrophil-
driven vasculitides have high HBP-levels (20). Furthermore, recent work has demonstrated 
that hypoxia can drive neutrophil activation and release of neutrophil granular proteins (21-
23). It is therefore reasonable that a few non-infected patients with several dysfunctional 
organs may have elevated HBP-levels. Importantly, as can be seen in figure 3, when 
comparing patients with the same degree of physiological disturbances, infected patients have 
significantly higher HBP-levels than non-infected patients. Previous studies have also shown 
that increased plasma- HBP is associated with development of septic acute kidney injury 
(AKI) in an intensive care cohort (24). This is in agreement with the present study where 
septic AKI was part of the organ dysfunction criterium. If septic AKI per se, as a result of 
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reduced kidney function, can increase plasma-HBP has not been studied in humans. 
Interestingly, preliminary data from a mouse model suggest that the main HBP-clearing 
organ is the liver and not the kidneys (Fisher et al manuscript in preparation) 
In this study, where the inclusion criteria favored inclusion of more severely ill patients and 
also non-infected patients, the ability of HBP to identify patients with infection-induced OD 
was lower than was the ability of CRP, in contrast to previous studies. Still, this study 
showed that there was an increase in HBP-levels with increasing number of organ 
dysfunction implying that HBP is a marker of disease severity. In addition to the use of 
biomarkers, several scores (e.g. qSOFA, NEWS2) are used in the ED to assess patients at risk 
for sepsis and infection-induced OD. HBP might have a role as an additional criterion when 
evaluating such scores and we are currently conducting such a study, where the patients from 
this study are part of the cohort (manuscript in preparation).   
The secondary outcome of this study, infection-related mortality or admittance to intensive 
care due to an infection, was analyzed with an additional post hoc criterion, SOFA-score ≥5 
after 12-24 hours due to an infection. This addition was made to compensate for not all 
seriously ill patients being admitted to intensive care. The AUC of HBP was 0.87 and highest 
among all biomarkers studied. 
The strengths of this prospective multicenter study are the large cohort of patients included at 
four different sites in three different countries, the careful blinding of HBP results when 
determining the cause of the disease and outcome, and the analysis of HBP at a central unit. 
All patients were also reviewed by at least two Infectious Diseases consultants to accurately 
determine the diagnosis. The study had inclusion criteria which focused on the enrollment of 
patients with a high risk of an impending OD and did not have any criterion focusing on 
singling out patients with infection. The cohort therefore reflects a wide spectrum of patients 
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that seek medical attention at the ED. Opposed to previous studies, this design can better 
determine the accuracy of HBP for identifying severe infections. The limitations of the study 
are the incomplete sample size for some of the comparative biomarkers, the missing data for 
a few patients and the hemolysis in 146 samples. However, in a sensitivity analysis inclusion 
of these patients did only change the AUCs to a very minor extent. Most patients were treated 
in regular wards and the measurements of vital parameters during follow-up could not be 
accomplished every hour, which also is a limitation.  
In conclusion, this is the first study evaluating the prognostic performance of HBP among 
patients, irrespective of the suspicion of an infection. HBP had a good performance in 
detecting infection-induced organ dysfunction but was outperformed by CRP against this 
outcome due to the excellent ability of CRP in detecting an infection. However, in a 
multivariable analysis CRP was not shown to be significantly associated with organ 
dysfunction but only to infection. This is opposed to HBP, which was associated with both 
infection and organ dysfunction.  HBP was furthermore shown to be the best biomarker to 
prognosticate the development of a critical infection. When using a cut-off of 22.85 ng/mL, 
HBP prognosticated a critical infection with a sensitivity of 78% and a specificity of 86%. 
The results further suggest that as HBP increases there is a concomitant increase in the risk 
for a critical infection. This may facilitate clinical decision-making. Based on this, it may be 
useful to have two cut-off levels of HBP; one lower for negative prospective purposes and 
one higher where special treatment should be initiated.  
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Legends 
Figure 1. Flow chart of patients in the study cohort. 
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Figure 2. HBP as a marker for infection-induced organ dysfunction  
Levels of HBP are shown for patients with and without OD and divided in 5 classes 
depending on the likelihood of infection. Boxes represent the first, second and third quartile 
with whiskers extending to the 10th and 90th percentile. The difference between groups was 
tested with the Mann-Whitney U-test. In the figure HBP-values >200 ng/mL was plotted at 
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Figure 3. HBP-levels increase with severity of disease  
Infected and non-infected patients (i.e. group I and IV from Figure 1) were included in this 
plot (n=332). The boxplots show the different numbers of failing organs within 72 hours. 
Boxes represent the first, second and third quartile with whiskers extending to the 10th and 
90th percentile. The Jonckheere-Terpstra test for trend was used to asses if HBP-levels 
increase as number of failing organs increase. The difference between groups was tested with 
the Mann-Whitney U-test. In the figure HBP-values >200 ng/mL was plotted at 200 ng/mL. 
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Figure 4 HBP as a prognostic test for critical infection  
Infected and non-infected patients (group I and IV) were included in this plot (n=332). Levels 
of HBP are shown for patients with and without critical disease. Boxes represent the first, 
second and third quartile with whiskers extending to the 10th and 90th percentile. The 
difference between groups was tested with the Mann-Whitney U-test. In the figure HBP-
values >200 ng/mL was plotted at 200 ng/mL. Horizontal lines represent 15 and 30 ng/mL 
which are cut-off levels suggested by previous studies. 
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Figure 5 The discriminatory properties of biomarkers change with the frequency of 
infection in the cohort. 
Infected and non-infected patients (group I and IV) were included in this plot (n=332, group I 
and IV). Samples from the two populations (infected, group I and non-infected, group IV) 
were drawn to mimic cohorts with the proportion of infected patients ranging from 10% to 
100% in steps of 1%. For each proportion of infected patients 100 stochastic cohorts were 
drawn with replacement and the AUC-values for the different biomarkers were calculated and 
the median was calculated and plotted. The vertical line represents the proportion of infected 
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Table 1. Baseline characteristics 
 N Infection 
N = 96 
Probable 
infection 







N = 69 
No  
infection 
N = 236 
Combined 
N = 524 
p-value 

































Warfarin 520 15% 
(14) 

















519 4% (4) 5% (4) 3% 
(1)




520 3% (3) 1% (1) 5% 
(2)
0% (0) 3% (7) 2% (13) 0.40 
Comorbidities 


























Renal  524 27% 
(26) 






15% (79) 0.01 
Respiratory 524 25% 36% 21% 39% 20% 26% 0.006 
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(24) (30) (8) (27) (48) (137) 






6% (14) 13% (67) <0.00001 
Liver 524 10% 
(10) 
2% (2) 3% 
(1)
4% (3) 3% (8) 5% (24) 0.09 
Malignancy 524 12% 
(12) 






12% (63) 0.79 
Immunodeficien
cy 
524 2% (2) 2% (2) 5% 
(2)
















Outcome   
ICU-admittance 
within 72 hours 
524 11% (11) 6% (5) 8% 
(3) 
14% (10) 11% (25) 10% (54) 0.49 
Mortality within 
72 hours 
524 2% (2) 4% (3) 0% 
(0) 
9% (6) 5% (12) 4% (23) 0.21 
Positive blood 
culture 
524 44% (42) 0% (0) 0% 
(0) 
0% (0) 0% (0) 8% (42) <0.00001 
SOFA at 
inclusion 
524 2 (1–4)   1.5(1–3) 2 (1– 
3)   




524       <0.00001 
0  22%% 
(21) 
31% (26) 33% 
(13) 
26% (18) 42% (99) 34% (177)  
1  21% (20) 32% (27) 46% 
(18) 
20% (14) 31% (72) 29% (151)  
2  27% (26) 17% (14) 8% 
(3) 
35% (24) 14% (34) 19% (101)  
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3  17% (16) 8% (7) 5% 
(2) 
4% (3) 6% (14) 8% (42)  
4  5% (5) 7% (6) 3% 
(1) 
6% (4) 1% (3) 4% (19)  
5  1% (1) 0% (0) 5% 
(2) 
0% (0) 1% (2) 1% (5)  
6  3 (3) 1% (1) 0% 
(0) 
0% (0) 0% (0) 1% (4)  
7  4%(4) 4% (3) 0% 
(0) 
9% (6) 5% (12) 5% (25)  
Diagnoses 524  
Infections         
Central nervous  1%  (1) 0%  (0) 0%  
(0) 
0%  (0) 0%  (0) 0%  (1)  
COPD 
exacerbation 
 0%  (0) 14%  (12) 3%  
(1) 
0%  (0) 0%  (0) 2%  (13)  
Endocarditis  4%  (4) 0%  (0) 0%  
(0) 
0%  (0) 0%  (0) 1%  (4)  
Gastrointestinal  3%  (3) 11%  (9) 10%  
(4) 
0%  (0) 0%  (0) 3%  (16)  
Genitourinary  25%  (24) 14%  (12) 0%  
(0) 
0%  (0) 0%  (0) 7%  (36)  
Influenza  0%  (0) 0%  (0) 46%  
(18) 
0%  (0) 0%  (0) 3%  (18)  
Other infection  2%  (2) 11%  (9) 0%  
(0) 
0%  (0) 0%  (0) 2%  (11)  
Respiratory  50%  (48) 37%  (31) 10%  
(4) 
0%  (0) 0%  (0) 16%  (83)  
Skin/soft tissue  5%  (5) 6%  (5) 0%  0%  (0) 0%  (0) 2%  (10)  




 9%  (9) 6%  (5) 0%  
(0) 
0%  (0) 0%  (0) 3%  (14)  
Viral  0%  (0) 1%  (1) 31%  
(12) 
0%  (0) 0%  (0) 2%  (13)  
         
Non-infectious 
causes 




 0% (0) 0% (0) 0% 
(0) 
0% (0) 1% (3) 1% (3)  
Cerebrovascula
r 
 0%  (0) 0%  (0) 0%  
(0) 
3%  (2) 6%  (15) 3% (17)  
CNS  0%  (0) 0%  (0) 0%  
(0) 
0%  (0) 2%  (4) 1%  (4)  
Diabetes  0%  (0) 0%  (0) 0%  
(0) 
1%  (1) 2%  (4) 1%  (5)  
Gastro  0%  (0) 0%  (0) 0%  
(0) 
9%  (6) 10%  
(24) 
6%  (30)  
Head trauma  0%  (0) 0%  (0) 0%  
(0) 
1%  (1) 2%  (4) 1%  (5)  
Heart rhythm  0%  (0) 0%  (0) 0%  
(0) 
0%  (0) 19%  
(46) 
9%  (46)  
Intoxication  0%  (0) 0%  (0) 0%  
(0) 
1%  (1) 4%  (10) 2%  (11)  
Kidney  0%  (0) 0%  (0) 0%  
(0) 
1%  (1) 3%  (6) 1%  (7)  
Liver  0%  (0) 0%  (0) 0%  
(0) 
0%  (0) 0%  (1) 0%  (1)  
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6%  (13) 7%  (39)  
Lung embolic  0%  (0) 0%  (0) 0%  
(0) 
4%  (3) 3%  (7) 2%  (10)  
Orthopedic  0%  (0) 0%  (0) 0%  
(0) 
1%  (1) 6%  (13) 3%  (14)  






12%  (65)  
Seizures  0%  (0) 0%  (0) 0%  
(0) 
3%  (2) 5%  (11) 2%  (13)  
Unspecified 
heart 
 0%  (0) 0%  (0) 0%  
(0) 
12%  (8) 9%  (21) 6%  (29)  
Vascular  0%  (0) 0%  (0) 0%  
(0) 
0%  (0) 3%  (6) 1%  (6)  
Continuous variables are displayed with median and inter-quartile range. Categorical variables are 
displayed with proportions and numbers within brackets. 
Non-categorical variables (Age, SOFA, Number of OD) are tested with Kruskal-Wallis tests and 
categorical variables with Pearson's chi-squared test or Fisher’s exact test, as appropriate. 
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Table 2. Discriminatory Values of Biomarkers for infection-induced organ dysfunction  
AUC, cut-off values, sensitivity, specificity, positive and negative likelihood ratio, positive 
predictive value and negative predictive value were calculated as well as the the 95% C.I. 
among infected and non-infected patients (n=332, group I and IV). The prevalence of 
infection-induced organ dysfunction was 23%. For HBP, WBC, CRP and lactate the cut-off 
values suggested by Youden’s index were used. For PCT commonly used cut-off values were 
used. The thresholds for HBP were also set to 15 ng/mL and 30 ng/mL, as suggested in prior 
publications(10,13). 
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Table 3. Discriminatory Value of Biomarkers for the diagnosis of critical infection  
AUC, cut-off values, sensitivity, specificity, positive and negative likelihood ratio, positive predictive 
value and negative predictive value were calculated as well as the the 95% C.I. among infected and 
non-infected patients (n=332, group I and IV). The prevalence of critical infection  was 4%. For HBP, 
WBC, CRP and lactate the cut-off values suggested by Youden’s index were used. For PCT 
commonly used cut-off values were used. The thresholds for HBP were also set to 15 ng/mL and 30 
ng/mL, as suggested in prior publications(10,13). The prevalence of critical infection was 4%. 
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Tabell 4. Predictors of elevated biomarkers. 
Among infected and non-infected patients (n=332, group I and IV) a logistic regressions were 
fitted using diochotimized biomarkers as outcomes with infection and organ dysfunction (A) 
or infection and critical disease (B) as covariates. The biomarkers were dichotomized 
according to their respective cut-off level suggested by the calculation of Youden’s index for 
each case. The corresponding odds ratios (ORs) were calculated and are displayed for 
infection and organ dysfunction (A) and for infection and critical disease (B).  
 
Table 4A. Infection and Organ dysfunction 
Biomarker Cut-off OR Infection OR Organ dysfunction 
HBP 13.7 8.97 (5.11-16.1) 3.01 (1.56-6.15) 
CRP 20.1 38.7 (18.9-87.2) 0.97 (0.50-1.86) 
PCT 0.15 5.46 (3.24-9.39) 1.57 (0.94-2.63) 
WBC 10.8 3.76 (2.28-6.28) 1.12 (0.68-1.85) 
Lactate 2.0 0.85 (0.48-1.53) 1.77 (0.96-3.36) 
 
 
Table 4B. Infection and Critical disease 
Biomarker Cut-off OR Infection OR Critical disease 
HBP 22.85 15.6 (7.4-36.2) 8.98 (3.57-23.9) 
CRP 120 51.9 (19.5-183.3) 3.45 (1.11-11.6) 
PCT 1 6.03 (3.35-11.1) 1.73 (0.71-3.97) 
WBC 17.55 7.86 (3.28-20.7) 6.91 (2.60-18.4) 
Lactate 2.65 0.99 (0.51-1.91) 2.51 (1.12-5.52) 
 
 
